PEGASYS

Apr 10, 2026

Summary  Three drugs that have been approved for PV include JAKAFI/JAKAVI (ruxolitinib), BESREMi (ropeginterferon alfa-2B/AOP2014/P1101), and PEGASYS (peginterferon alfa-2a). JAKAFI and BESREMi are approved in the US, Europe, and Japan, while PEGASYS is approved only in Europe. JAKAFI is nearing its pat...

Sep 29, 2025

Affecting roughly 1–2 people per 100,000 each year, essential thrombocythemia is often silent, discovered during routine blood tests, yet it can quietly impact quality of life. The total number of diagnosed cases of essential thrombocythemia in the US was approximately 167,000 cases in 2024. In the United States, t...